KR20210107176A - 크론병과 연관된 tnfsf15와 dcr3의 변이체 - Google Patents

크론병과 연관된 tnfsf15와 dcr3의 변이체 Download PDF

Info

Publication number
KR20210107176A
KR20210107176A KR1020217026836A KR20217026836A KR20210107176A KR 20210107176 A KR20210107176 A KR 20210107176A KR 1020217026836 A KR1020217026836 A KR 1020217026836A KR 20217026836 A KR20217026836 A KR 20217026836A KR 20210107176 A KR20210107176 A KR 20210107176A
Authority
KR
South Korea
Prior art keywords
seq
tnfsf15
variants
disease
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217026836A
Other languages
English (en)
Korean (ko)
Inventor
더모트 피. 맥거번
Original Assignee
세다르스-신나이 메디칼 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세다르스-신나이 메디칼 센터 filed Critical 세다르스-신나이 메디칼 센터
Priority to KR1020237020524A priority Critical patent/KR20230093538A/ko
Publication of KR20210107176A publication Critical patent/KR20210107176A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217026836A 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체 Ceased KR20210107176A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237020524A KR20230093538A (ko) 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361824932P 2013-05-17 2013-05-17
US61/824,932 2013-05-17
PCT/US2014/038468 WO2014186750A2 (en) 2013-05-17 2014-05-16 Variants of tnfsf15 and dcr3 associated with crohn's disease
KR1020157034355A KR102295125B1 (ko) 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157034355A Division KR102295125B1 (ko) 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237020524A Division KR20230093538A (ko) 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체

Publications (1)

Publication Number Publication Date
KR20210107176A true KR20210107176A (ko) 2021-08-31

Family

ID=51899024

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020217026836A Ceased KR20210107176A (ko) 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체
KR1020257028341A Pending KR20250130857A (ko) 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체
KR1020157034355A Active KR102295125B1 (ko) 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체
KR1020237020524A Ceased KR20230093538A (ko) 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020257028341A Pending KR20250130857A (ko) 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체
KR1020157034355A Active KR102295125B1 (ko) 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체
KR1020237020524A Ceased KR20230093538A (ko) 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체

Country Status (7)

Country Link
US (4) US20160090629A1 (enExample)
EP (3) EP2997165A4 (enExample)
JP (5) JP6482533B2 (enExample)
KR (4) KR20210107176A (enExample)
CN (1) CN105358713B (enExample)
ES (1) ES2894963T3 (enExample)
WO (1) WO2014186750A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
EP3495389A1 (en) 2011-09-30 2019-06-12 Teva Pharmaceuticals Australia Pty Ltd Antibodies against tl1a and uses thereof
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
KR20210107176A (ko) 2013-05-17 2021-08-31 세다르스-신나이 메디칼 센터 크론병과 연관된 tnfsf15와 dcr3의 변이체
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
HK1257443A1 (zh) 2015-08-21 2019-10-18 The Children's Hospital Of Philadelphia 治疗具有dcr3或dcr3网络基因中的遗传变异的患者的自身免疫病症的方法
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
KR20230003433A (ko) * 2016-05-20 2023-01-05 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
CN121371183A (zh) * 2018-09-07 2026-01-23 费城儿童医院 用于淋巴系统病症的诊断和治疗的组合物和方法
EP3969621A4 (en) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES
CN122060049A (zh) * 2019-09-13 2026-05-19 协和麒麟株式会社 DcR3变体
IL302791A (en) * 2020-11-13 2023-07-01 Prometheus Biosciences Inc Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
IL325993A (en) 2023-08-11 2026-03-01 Paragon Therapeutics Inc TL1A binding proteins and methods of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20090186034A1 (en) * 2006-12-19 2009-07-23 Genetech, Inc. Gene expression markers for inflammatory bowel disease
US20100190162A1 (en) 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2009052512A2 (en) 2007-10-19 2009-04-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
HRP20150684T1 (hr) * 2008-02-19 2015-09-11 The Children's Hospital Of Philadelphia, Abramson Pediatric Research Center, Office of Technology Transfer Identifikacija specifiäśnih mjesta nastanka - genetski loci - upalne bolesti crijeva kod djece i postupci njihove uporabe u takvoj dijagnozi te njihovo lijeäśenje
WO2010118210A1 (en) * 2009-04-08 2010-10-14 Cedars-Sinai Medical Center Methods of predicting complication and surgery in crohn's disease
NZ619527A (en) * 2009-04-14 2015-06-26 Nestec Sa Inflammatory bowel disease prognostics
WO2012054532A1 (en) 2010-10-18 2012-04-26 Prometheus Laboratories Inc. Methods for determining anti-drug antibody isotypes
MX343327B (es) 2011-02-17 2016-11-01 Nestec Sa Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa.
AU2012259312A1 (en) * 2011-05-20 2013-12-12 Government Of The United States, As Represented By The Secretary Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
US20140170157A1 (en) 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
EP2565277A1 (en) 2011-09-05 2013-03-06 Progenika Biopharma, S.A. Method for predicting radiographic severity in ankylosing spondylitis
WO2013059732A1 (en) 2011-10-21 2013-04-25 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
KR20210107176A (ko) 2013-05-17 2021-08-31 세다르스-신나이 메디칼 센터 크론병과 연관된 tnfsf15와 dcr3의 변이체
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法

Also Published As

Publication number Publication date
US12281359B2 (en) 2025-04-22
KR20250130857A (ko) 2025-09-02
WO2014186750A3 (en) 2015-01-08
US20160090629A1 (en) 2016-03-31
ES2894963T3 (es) 2022-02-16
EP3498867A1 (en) 2019-06-19
EP2997165A4 (en) 2017-03-08
CN105358713B (zh) 2020-02-28
CN105358713A (zh) 2016-02-24
JP2025023316A (ja) 2025-02-14
EP3498867B1 (en) 2021-09-29
EP3988673A3 (en) 2022-08-03
US20180230543A1 (en) 2018-08-16
KR20230093538A (ko) 2023-06-27
JP2022111329A (ja) 2022-07-29
EP2997165A2 (en) 2016-03-23
WO2014186750A2 (en) 2014-11-20
KR20160009582A (ko) 2016-01-26
JP2020127437A (ja) 2020-08-27
US20210371931A1 (en) 2021-12-02
JP2018148931A (ja) 2018-09-27
JP6482533B2 (ja) 2019-03-13
ES2894963T8 (es) 2022-02-24
US20250243548A1 (en) 2025-07-31
EP3988673A2 (en) 2022-04-27
JP2016526875A (ja) 2016-09-08
KR102295125B1 (ko) 2021-08-31

Similar Documents

Publication Publication Date Title
KR102295125B1 (ko) 크론병과 연관된 tnfsf15와 dcr3의 변이체
Maltby et al. Genome-wide DNA methylation changes in CD19+ B cells from relapsing-remitting multiple sclerosis patients
KR20180127416A (ko) Rnaset2를 통한 염증성 장 질환의 진단 방법
JP2015516979A (ja) Ｃｒｈ過剰活性を有する患者の治療に用いるためのｃｒｈｒ１アンタゴニスト
EP3011048B1 (en) Method for predicting a treatment response to a v1b antagonist in a patient with depressive and/or anxiety symptoms
DK3277835T3 (en) GENETIC PREDICTORS OF A REACTION ON TREATMENT WITH CRHR1 ANTAGONISTS
US20160096885A1 (en) Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis
Glas et al. The role of osteopontin (OPN/SPP1) haplotypes in the susceptibility to Crohn's disease
AU2016240213B2 (en) Method of treatment using genetic predictors of a response to treatment with CRHR1 antagonists
Szczepańska et al. Involvement of vascular endothelial growth factor-460 C/T,+ 405 G/C and+ 936 C/T polymorphisms in the development of endometriosis
Sakalar et al. Higher frequency of rs4977574 (the G Allele) on chromosome 9p21. 3 in patients with myocardial infarction as revealed by PCR-RFLP analysis
Sayad et al. The association of-475 and-631 interleukin-2 gene polymorphism with multiple sclerosis in Iranian patients
JP6004287B2 (ja) コフィン−シリス症候群の検出方法
US20100285455A1 (en) Prediction of schizophrenia risk using homozygous genetic markers
HK40072596A (en) Variants of tnfsf15 and dcr3 associated with crohn's disease
TW201701897A (zh) 選擇對醋酸格拉替雷（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之反應具預測性之單一核苷酸多型性
Höffler et al. Epigenome-Wide Association Studies in Cases and Controls With High and Low Genetic Risk for Schizophrenia
Davatchi et al. HLA-B51 IN BEHCETS DISEASE
WO2016141441A1 (en) Treatment and detection of inflammatory disease
Zhou et al. Epigenome-wide Association Study (EWAS) of BMI, BMI Change, and Waist Circumference in African American Adults Identifies Multiple Replicated Loci

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210824

Application number text: 1020157034355

Filing date: 20151202

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210914

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211005

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220801

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211005

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220801

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210914

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20230119

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20230102

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20220801

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20211005

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210914

X601 Decision of rejection after re-examination